SZM679

SZM679 is a potent, orally active and selective RIPK1 inhibitor with Kd values of 8.6 nM and >5000 nM for RIPK1 and RIPK3, respectively. SZM679 reverses the tumor necrosis factor-induced systemic inflammatory response. SZM679 decreases the Tau hyperphosphorylation, neuroinflammation, and the RIPK1 phosphorylation level in the hippocampus and cortex. SZM679 can be used in research of Alzheimer's disease (AD) [1].

Product Specifications

CAS Number

[3027645-52-6]

UNSPSC

12352005

Target

RIP kinase

Type

Reference compound

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/szm679.html

Purity

99.59

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1CC(C1)=O)NC2=NC3=CC(F)=C(OC4=CC=C(F)C(NC(CC5=CC=CC(OC(F)(F)F)=C5)=O)=C4)C=C3S2

Molecular Formula

C27H18F5N3O5S

Molecular Weight

591.51

References & Citations

[1]Sun Y, et, al. Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease. J Med Chem. 2022 Nov 10;65 (21) :14957-14969.